Amicus Therapeutics reports Q4 profit with 30% growth in product sales

From Nasdaq: 2025-02-19 07:49:08

Amicus Therapeutics reported a net income of $14.7 million, or $0.05 per share for the fourth quarter, a significant improvement from a net loss of $33.8 million, or $0.11 per share a year ago. Excluding one-time items, earnings were $29.2 million or $0.09 per share compared to $2.6 million or $0.01 per share last year. Product sales saw a 30 percent increase to $149.71 million. Analysts expected earnings of $0.09 per share on revenue of $147.87 million. The company anticipates revenue growth of 17 percent – 24 percent for fiscal 2025, with positive net income expected in the second half of the year.



Read more at Nasdaq: Amicus Therapeutics Turns To Q4 Profit; Product Sales Grow 30%